HIV/HBV co-infection and rate of antiretroviral treatment change after highly active antiretroviral treatment initiation in a cohort of HIV-infected patients in Greece

International Journal of STD and AIDS

Volumn 21, Issue 10, 2010, Pages 702-707

  Nikolopoulos, G K ^a   Paraskevis, D ^a   Hatzitheodorou, E ^a   Moschidis, Z ^a   Sypsa, V ^a   Zavitsanos, X ^a   Kalapothaki, V ^a   Hatzakis, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antiretroviral; Co infection; HAART; Hepatitis B; Hepatotoxicity; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMORBIDITY; FEMALE; GREECE; HEMOPHILIA; HEPATITIS B; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SEROLOGY; STATISTICAL MODEL; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS HEPATITIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GREECE; HEPATITIS B; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 78650096367     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010112     Document Type: Article

References (28)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60 (Pubitemid 28135961)
2. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601 (Pubitemid 40543982)
3. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009;48:1763-71
4. Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. Australian HIV Observational Database. HIV Med 2002;3:28-36
5. Petoumenos K, Ringland C. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Med 2005;6:155-63 (Pubitemid 40740331)
6. Petoumenos K. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database. J Clin Virol 2003;26:209-22 (Pubitemid 36206605)
7. Pandeya N, Purdie DM, Green A, Williams G. Repeated occurrence of basal cell carcinoma of the skin and multi-failure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol 2005;161:748-54
8. Glynn RJ, Buring JE. Ways of measuring rates of recurrent events. BMJ 1996;312:364-7 (Pubitemid 26049407)
9. Clayton D. Random effects Poisson regression and recurrent events data [abstract]. Presented at the Fifth UK Stata User Group Meeting, London, United Kingdom, 17-18 May 1999
10. Cleves M, Cañette I. How Do I Analyze Multiple Failure-Time Data Using Stata. Texas: Stata Corporation, 2009. See www.stata.com/support/faqs/ stat/stmfail.html (last checked July 2009)
11. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Statist 1982;10:1100-20
12. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrica 1981;68:373-9
13. Collett D. Modelling Survival Data in Medical Research. Boca Raton: Chapman & Hall/CRC, 1999
14. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-5
15. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004;18:1169-77 (Pubitemid 38738516)
16. Lincoln D, Petoumenos K, Dore GJ. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med 2003;4:241-9 (Pubitemid 36949880)
17. De Luca A, Bugarini R, Lepri AC, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002;162:2125-32 (Pubitemid 35168221)
18. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-902 (Pubitemid 32042753)
19. Cooper CL, Mills E. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection. Int J STD AIDS 2007;18:546-50 (Pubitemid 351738943)
20. Klein MB, Willemot P, Murphy T, et al. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004;18:1895-904 (Pubitemid 39313205)
21. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6 (Pubitemid 35472132)
22. Omland LH, Weis N, Skinhøj P, et al. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med 2008;9:300-6 (Pubitemid 351517277)
23. Savès M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999;13:F115-21
24. Savès M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000;44:3451-5 (Pubitemid 33009512)
25. Cicconi P, Cozzi-Lepri A, Phillips A, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007;21:599-606
26. Torti C, Lapadula G, Uccelli MC, et al. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents 2007;29:185-90 (Pubitemid 46073664)
27. Iser DM, Lewin SR. Future directions in the treatment of HIV-HBV coinfection. HIV Ther 2009;3:405-15
28. Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 2005;56:1087-93 (Pubitemid 43009825)